Replies to post #78176 on Biotech Values

[alfabeta]

ONXX and Bayer
Wonder how can a big phama modify its biotech partner product and get 100% of the next generation drug's sale. If there is a legal leeway to do that, all small bioteches shall be very careful. What probability can onxx win over it?

[poorgradstudent]

Re: GNVC

I'm going to keep my mouth shut until the data are out at ASCO. It's probably the prudent thing to do ;-)

On another note, it appears that a long time borderline program, phenoxodiol, is about to come to an end:

Pivotal trial stopped at ~1/3rd enrollment:

http://www.novogen.com/news/news0501.cfm?mainsection=05&subsection=01&newsid=320

From the former CEO / Chairman:

http://www.kellymusings.com/ovature.php